以第一作者/通讯作者发表代表性SCI文章如下：
1.Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2. Redox biology vol. 52 (2022): 102310. doi:10.1016/j.redox.2022.102310 2.A new FGF1 variant protects against adriamycin-induced cardiotoxicity via modulating p53 activity. Redox biology vol. 49 (2022): 102219. doi:10.1016/j.redox.2021.102219 3.Metallothionein Is Downstream of Nrf2 and Partially Mediates Sulforaphane Prevention of Diabetic Cardiomyopathy. Diabetes vol. 66,2 (2017): 529-542. doi:10.2337/db15-1274 4.Metallothionein Preserves Akt2 Activity and Cardiac Function via Inhibiting TRB3 in Diabetic Hearts. Diabetes vol. 67,3 (2018): 507-517. doi:10.2337/db17-0219 5.Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability. Cell reports vol. 20,7 (2017): 1717-1728. doi:10.1016/j.celrep.2017.06.063 6.Curtailing FGF19's mitogenicity by suppressing its receptor dimerization ability. Proc Natl Acad Sci U S A vol. 117,46 (2020): 29025-29034. doi:10.1073/pnas.2010984117 7.Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo. Eur J Cancer vol. 50,6 (2014): 1184-94. doi:10.1016/j.ejca.2013.12.027 8.Regulatory role of endogenous and exogenous fibroblast growth factor 1 in the cardiovascular system and related diseases.Pharmacological research vol. 169 (2021): 105596. doi:10.1016/j.phrs.2021.105596 9.Regulatory mechanisms of Sesn2 and its role in multi-organ diseases. Pharmacological research vol. 164 (2021): 105331. doi:10.1016/j.phrs.2020.105331 10.Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways. Cellular and molecular life sciences : CMLS vol. 78,7 (2021): 3105-3125. doi:10.1007/s00018-020-03729-y 11.Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo. Cancer Lett vol. 343,2 (2014): 200-9. doi:10.1016/j.canlet.2013.10.011 12.Cardioprotective effects of fibroblast growth factor 21 against doxorubicin-induced toxicity via the SIRT1/LKB1/AMPK pathway. Cell Death Dis. vol. 8,8 e3018. 24 Aug. 2017, doi:10.1038/cddis.2017.410 13.Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis. Cell Death Dis. vol. 9,2 82. 23 Jan. 2018, doi:10.1038/s41419-017-0093-5 14.NRF2-Related Epigenetic Modifications in Cardiac and Vascular Complications of Diabetes Mellitus. Frontiers in endocrinology vol. 12 598005. 25 Jun. 2021, doi:10.3389/fendo.2021.598005 15.Epigenetic Regulation Associated With Sirtuin 1 in Complications of Diabetes Mellitus. Frontiers in endocrinology vol. 11 598012. 18 Jan. 2021, doi:10.3389/fendo.2020.598012 16.The Role of Fibroblast Growth Factor 21 in Diabetic Cardiovascular Complications and Related Epigenetic Mechanisms. Frontiers in endocrinology vol. 12 598008. 19 Jul. 2021, doi:10.3389/fendo.2021.598008 17.Resveratrol and FGF1 Synergistically Ameliorates Doxorubicin-Induced Cardiotoxicity via Activation of SIRT1-NRF2 Pathway. Nutrients, vol. 14, no. 19, Sept. 2022, p. 4017. Crossref, https://doi.org/10.3390/nu14194017. 18.Resveratrol Attenuates High Glucose-Induced Osteoblast Dysfunction via AKT/GSK3β/FYN-Mediated NRF2 Activation. Frontiers in pharmacology vol. 13 862618. 23 May. 2022, doi:10.3389/fphar.2022.862618 19.Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway. Frontiers in pharmacology, vol. 13 940406. 30 Aug. 2022, doi:10.3389/fphar.2022.940406 |
